Hi [[ session.user.profile.firstName ]]

ヒトiPS細胞由来高品質心筋細胞の大量作製法の開発と心臓再生医療への応用

ヒトiPS細胞から作製した心筋細胞を用いた再生医療を実現化するにはさまざまな課題を克服する必要があります。本セミナーではその課題を克服するためのアプローチを紹介します。

ポイント:
・ヒトiPS細胞を用いた再生医療における課題について 
・ヒトiPS細胞から心筋細胞を大量に作製・回収する方法について
・ヒトiPS細胞由来の分化細胞集団から心筋細胞のみを選別する方法について 
・ヒトiPS細胞由来の心筋スフェロイドを大量に作製する方法について
Recorded Jun 23 2020 70 mins
Your place is confirmed,
we'll send you email reminders
Presented by
慶應義塾大学循環器内科 臓器再生医学寄附講座 特任講師 遠山周吾先生
Presentation preview: ヒトiPS細胞由来高品質心筋細胞の大量作製法の開発と心臓再生医療への応用

Network with like-minded attendees

  • [[ session.user.profile.displayName ]]
    Add a photo
    • [[ session.user.profile.displayName ]]
    • [[ session.user.profile.jobTitle ]]
    • [[ session.user.profile.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(session.user.profile) ]]
  • [[ card.displayName ]]
    • [[ card.displayName ]]
    • [[ card.jobTitle ]]
    • [[ card.companyName ]]
    • [[ userProfileTemplateHelper.getLocation(card) ]]
  • Channel
  • Channel profile
  • Maximizing Cell Yields Using Perfusion - POSTPONED Jun 3 2021 5:00 pm UTC 60 mins
    Dr. Ann Rossi
    As cell therapy trials advance from pre-clinical research to late-stage trials, cell culture platforms will need to meet increasing demands for cell yield. The Corning® CellCube® system provides a simple, compact, and scalable method for mass culture of attachment-dependent cells. In this webinar, we present data supporting expansion of two commonly used bioproduction cell lines – HEK293T and Vero. The basic closed system was configured with a peristaltic pump to drive continuous circulation through the CellCube 100-layer module and paired with the Eppendorf BioFlo® 120 controller with a BioBLU® 3c single-use bioreactor for medium conditioning. The controller simplified oxygenation and pH control of the circulating medium. Medium conditioning in the SUB was sufficient to sustain both HEK293T and Vero cell growth in the CellCube 100-layer module for 5- and 6-day expansions, respectively. Final harvest yields for both HEK293T and Vero cell lines greater than 10 billion cells demonstrate the utility of the CellCube system for mass culture of adherent cell lines with efficient medium usage.

    About the Presenter:
    Dr. Ann E. Rossi graduated from the University of Rochester School of Medicine and Dentistry with a Ph.D. in Pharmacology and received postdoctoral training at the University of Chicago. Ann began her career with Corning Life Sciences as the Applications Lab Manager where she utilized her strong academic and industry research experience to direct the activities of the Applications Laboratory. Currently, Dr. Rossi is the Senior Bioprocess Applications Scientist, functioning as the technical lead for generating applications in support of Corning Life Sciences’ Bioprocess and Cell/Gene Therapy portfolios including CellCube and HYPERStack platforms.
  • 3D Cell Cultures and Tissue Clearing Sep 17 2020 4:00 pm UTC 60 mins
    Ian MacCloud, Laboratory Manager at Visikol Inc.
    In this webinar, Visikol Laboratory Manager Ian MacCloud will provide an overview of best practices when imaging 3D cell culture models and how to employ tissue clearing for improved imaging. Mr. MacCloud will review different high content imaging systems as well as important considerations for how best to image a 3D cell culture model. Additionally, Mr. MacCloud will provide several case studies in which tissue clearing and high content confocal microscopy is integral to addressing specific research questions:
    • LED vs laser illumination
    • Dipping vs air objectives
    • Basic principles of confocal microscopy
    • Best practices for labeling 3D cell culture models
    • Wide field vs confocal imaging
    • 3D image analysis

    Speaker Bio:
    Ian MacCloud is the Laboratory Manager at Visikol and a Rutgers University alumni with a background in molecular biology. Ian's research background has primarily focused on the fields of biofuels, analytic chemistry, pharmaceutical engineering, 3D cell culture models, and histology. Ian has experience in both pure research environments such as at Robert Wood Johnson (formerly UMDNJ), as well as commercial R&D labs such as the labs of The Rutgers EcoComplex and the Medical Cannabis Research Foundation. Ian has worked with multiple life science startup companies where he has found a passion for commercializing the insights gleaned from basic research in the biological sciences.
  • Organogenesis to Oncogenesis Sep 15 2020 2:00 pm UTC 45 mins
    Dr. Joseph Regan
    Organogenesis to Oncogenesis: Modeling Development and Cancer with Organoids
    Organoid cell culture allows mammalian stem cells to differentiate and self-organize into three-dimensional organ-like tissues that reflect the key structural and functional properties of the organs from which they are derived. In addition, organoids can be grown from patient-derived healthy and tumor tissue to provide genetically and phenotypically stable personalized preclinical models. Organoid technologies therefore provide a unique in vitro system in which to study human organ development and cancer.

    In this webinar, Dr. Regan will discuss the use of organoid technologies to study organogenesis and cell fate determination in the postnatal mammary gland. In addition, the use of patient-derived organoids (PDOs) to elucidate the molecular mechanisms that regulate oncogenesis and contribute to tumor heterogeneity in colon cancer will be discussed.

    Presenter:
    Dr. Joseph Regan graduated from The Institute of Cancer Research (University of London, UK) with a Ph.D. in Cell Biology and received postdoctoral training at the Breast Cancer Now Research Centre (London, UK) and the Max Planck Institute for Molecular Genetics (Berlin, Germany). Dr. Regan subsequently worked as a Research Scientist with Bayer AG and the Charité Medical University (Berlin, Germany), where he uses patient-derived organoid models to study cancer stem cells and tumor heterogeneity in colon cancer.
  • 最新バイオロジクス技術を用いた細胞・遺伝子治療開発の海外導入事例を紹介 Sep 8 2020 6:00 am UTC 60 mins
    コーニングインターナショナル株式会社  ライサイエンス事業部 石渡 孝至
    欧米を中心に実用化が加速し始めた細胞・遺伝子治療分野の幹細胞やウイルスベクターの産業化に向け、コーニング独自のハイパーテクノロジー(HYPERFlask®、HYPERStack®)を中心にクローズドシステムによる無菌操作法や最終製剤化の安全操作性について概説いたします。
  • Generando un Microambiente Óptimo en Todas las Etapas del Cultivo Celular Aug 28 2020 2:00 pm UTC 30 mins
    Constanza Curotto
    Corning y Aplicaciones en Bioprocesos: Medio de Cultivo y Suero - Parte 3/3

    El medio de cultivo y suero son componentes esenciales del cultivo celular – suministrando nutrientes y factores claves para las células – en ese sentido, seleccionar los productos óptimos es esencial.
    En este Webinar presentaremos una revisión general del porfolio de medio y suero de Corning, y como estos productos pueden ser usados en aplicaciones de bioprocesos para realzar tanto procesos de producción e investigación.
    El portfolio de Corning incluye:
    -Diversas formulaciones de medio estándar para requerimientos específicos
    -Medio libre de suero y medios especializados
    -Suero estándar y premium
    -Selección de suero especializado.

    Biografía del Expositor
    Luego de graduarse como Bioquímico de la Universidad de Santiago de Chile, Constanza prosiguió su carrera en la industria farmacéutica veterinaria, desempeñándose como Científico de Bioprocesos tanto para el desarrollo de vacunas bacterianas y virales, estando a cargo de los procesos de escalado y generación de antígenos. Luego continuo su carrera en Bélgica, esta vez en el área de la producción de anticuerpos y proteínas recombinantes en sistemas celulares en suspensión, generando optimización de protocolos y experimentos de escalado.
  • Multiplica Tus Células, No Tu Trabajo: Cómo Escalar Cultivos en Suspensión Aug 27 2020 4:00 pm UTC 30 mins
    Constanza Curotto
    Corning y Aplicaciones en Bioprocesos: Células en Suspensión - Parte 2/3

    Los procesos en suspensión juegan un rol clave en el mercado de biofarmacéuticos, donde sistemas celulares en suspensión son usados para producir anticuerpos y proteínas recombinantes. En este contexto, la selección de las plataformas de cultivo adecuadas favorece el uso eficiente del espacio, reduce costos y horas de trabajo. En este Webinar haremos una revisión general del portfolio de Corning para el cultivo en suspensión, aplicado tanto al ámbito de la investigación y desarrollo y producción. Apoyado además con datos experimentales generados por nuestros equipos de desarrollo.

    Biografía del Expositor
    Luego de graduarse como Bioquímico de la Universidad de Santiago de Chile, Constanza prosiguió su carrera en la industria farmacéutica veterinaria, desempeñándose como Científico de Bioprocesos tanto para el desarrollo de vacunas bacterianas y virales, estando a cargo de los procesos de escalado y generación de antígenos. Luego continuo su carrera en Bélgica, esta vez en el área de la producción de anticuerpos y proteínas recombinantes en sistemas celulares en suspensión, generando optimización de protocolos y experimentos de escalado.
  • Corning HYPER Technologies: Compact Solutions for Cell Scale-Up [ENG. VERSION] Aug 27 2020 3:00 pm UTC 45 mins
    Dr. Lindsey Parker
    Efficient cell scale-up is essential in biologics and vaccine production to facilitate optimal product yields, whilst reducing footprint and manhours, Corning introduces the HYPER vessel technology. Corning HYPERFlasks and HYPERStacks are multilayer vessels incorporating proprietary gas-permeable film technology, resulting in high surface area to volume ratio. Using HYPER vessels, scientists can generate greater yields than traditional cell culture technologies, saving time, space and labor.

    In this webinar we will provide a general introduction of the HYPER technology, as well as technical applications in the fields of cell and gene therapy and viral particle production.

    About presenters:

    Dr. Lindsey Parker
    Lindsey completed her Ph.D. in Tissue Engineering and Regenerative Medicine at the University of Leeds (UK), validating a bioreactor for the application of mechanical stimuli to MSC. She subsequently joined UCL as an industrial KTP associate, leading clinical research in umbilical cord- derived MSC scale-up in collaboration with a tissue bank. Lindsey is currently a Bioprocess Sales Specialist at Corning, providing specialist support in bioprocess ranges, such as advising on product selection, custom products, and providing training.
  • Corning HYPER Technologies: Compact Solutions for Cell Scale-Up [SP. VERSION] Aug 27 2020 1:30 pm UTC 45 mins
    Constanza Curotto
    Efficient cell scale-up is essential in biologics and vaccine production to facilitate optimal product yields, whilst reducing footprint and manhours, Corning introduces the HYPER vessel technology. Corning HYPERFlasks and HYPERStacks are multilayer vessels incorporating proprietary gas-permeable film technology, resulting in high surface area to volume ratio. Using HYPER vessels, scientists can generate greater yields than traditional cell culture technologies, saving time, space and labor.

    In this webinar we will provide a general introduction of the HYPER technology, as well as technical applications in the fields of cell and gene therapy and viral particle production.
    About presenter:

    Constanza Curotto
    After graduating from Biochemistry in the University of Santiago (Chile), Constanza pursued directly a career in the Chilean Vaccine R&D industry, developing as a bioprocess scientist for both bacterial and viral vaccines in the field of animal health, being in charge of scale-up, and tech transfer with manufacturing plants. She furthered developed her career in Belgium as a bioprocess scientist, this time in the field of recombinant protein production, pursuing protocol optimization and scale-up experiments with suspension mammalian cell lines. Constanza is currently a field applications scientist in Corning for the EMEA region, providing customers with in-depth technical support, presenting seminars and trainings, and assisting customers in experimental set-up and troubleshooting.
  • Corning HYPER Technologies: Compact Solutions for Cell Scale-Up [FR. VERSION] Aug 27 2020 12:00 pm UTC 45 mins
    Dr. Sonia Meconi
    Efficient cell scale-up is essential in biologics and vaccine production to facilitate optimal product yields, whilst reducing footprint and manhours, Corning introduces the HYPER vessel technology. Corning HYPERFlasks and HYPERStacks are multilayer vessels incorporating proprietary gas-permeable film technology, resulting in high surface area to volume ratio. Using HYPER vessels, scientists can generate greater yields than traditional cell culture technologies, saving time, space and labor.

    In this webinar we will provide a general introduction of the HYPER technology, as well as technical applications in the fields of cell and gene therapy and viral particle production.

    About presenters:

    Dr. Sonia Meconi
    Sonia’s scientific background covers different fields such as biochemistry, cell biology, and immunology where she obtained a Ph.D., specifically in human infectious diseases working on a daily basis in a biologic level 3 lab. After a post-doctoral fellow and lecturer experience, she took over the head of the R&D and production teams in a small biotech which developed human serological diagnosis assays for infectious and autoimmune diseases. She oversaw pathogens (bacteria and virus) expansion supervision for protein microarray tests. Then, she joined an international company as an Application Specialist for cell culture and purification, creating new cell culture media dedicated to vaccines and cell therapy markets. Now, she joined Corning as Bioprocess Specialist working for different suppliers for the biopharmaceutical industry.
  • Corning HYPER Technologies: Compact Solutions for Cell Scale-Up [GER. VERSION] Aug 27 2020 9:00 am UTC 45 mins
    Dr. Franziska Wienholz
    Efficient cell scale-up is essential in biologics and vaccine production to facilitate optimal product yields, whilst reducing footprint and manhours, Corning introduces the HYPER vessel technology. Corning HYPERFlasks and HYPERStacks are multilayer vessels incorporating proprietary gas-permeable film technology, resulting in high surface area to volume ratio. Using HYPER vessels, scientists can generate greater yields than traditional cell culture technologies, saving time, space and labor.

    In this webinar we will provide a general introduction of the HYPER technology, as well as technical applications in the fields of cell and gene therapy and viral particle production.

    About Presenter:

    Dr. Franziska Wienholz
    Franziska completed her Ph.D. in Molecular Genetics at the Erasmus MC,The Netherlands, focusing on studying DNA repair and related diseases. During her research, she acquired extensive knowledge on cell culture and patient-derived materials, molecular techniques, and genome editing.
  • Multiplica Tus Células, No Tu Trabajo: Cómo Escalar Cultivos Adherentes Aug 26 2020 2:00 pm UTC 30 mins
    Constanza Curotto
    Corning y Aplicaciones en Bioprocesos: Células Adherentes - Parte1/3

    Un escalado eficiente es esencial en la producción de fármacos biológicos; el tipo celular, aplicación y espacio dictan cual es la plataforma más adecuada para cada proceso. En este Webinar haremos una revisión general de las plataformas de cultivo de Corning para células adherentes, y como estos pueden ser empleados para el escalado en aplicaciones de bioproduccion tales como producción de vacunas, terapias celulares y producción de vectores virales.

    Biografía del Expositor:
    Luego de graduarse como Bioquímico de la Universidad de Santiago de Chile, Constanza prosiguió su carrera en la industria farmacéutica veterinaria, desempeñándose como Científico de Bioprocesos tanto para el desarrollo de vacunas bacterianas y virales, estando a cargo de los procesos de escalado y generación de antígenos. Luego continuo su carrera en Bélgica, esta vez en el área de la producción de anticuerpos y proteínas recombinantes en sistemas celulares en suspensión, generando optimización de protocolos y experimentos de escalado.
  • Harnessing the Power of 3D Spheroids in Cancer Research Aug 25 2020 5:00 am UTC 60 mins
    Roxana Ghadessy, Ph.D. and Fiona Chang, Ph.D.
    In this joint webinar, Corning and Promega will present tools and solutions to support the continuous evolution of the spheroid model in 3D cell culture applications. Learn about how culture platforms optimized for single spheroid analysis or mass spheroid production can be coupled with novel real-time cell health assays and total RNA purification techniques. Furthermore, learn how to expand the spheroid workflow with downstream analysis of miRNA effects in cancer cell growth and metastasis.

    1. Turning the volume up on spheroid production with Corning Elplasia™ microplates - Roxana Ghadessy, Ph.D.

    Roxana is a Technical Marketing Manager for Corning Life Sciences, based in Singapore. In this role she is responsible for product awareness and education activities to highlight Corning’s workflow solutions in Cell Culture, Drug Discovery and other differentiated applications. Roxana has held previous roles in Sales and Product Management at Corning, BD Biosciences and Tocris. She received her Ph.D. degree in Pharmacology from the University of Bristol.

    2. A Complete Workflow for MicroRNA Analysis Paired with Novel Cell Health Assays for 3D Cultures - Fiona Chang, Ph.D.

    Fiona is an Applications Scientist at Promega Corporation, based in Singapore. She facilitates adoption of products by performing demonstrations, troubleshooting experiments, and giving trainings. Prior to joining Promega, Fiona received her Ph.D. in Biochemistry and Molecular Biology from Monash University, Melbourne. She has been working as a research fellow at the National University of Singapore before joining the Scientific Applications Group in 2018. Fiona has since been involved in applications in the Genomics, Genetic Identity, Applied Markets, Clinical Diagnostics and Cellular Analysis product areas.
  • A breath of fresh air with Corning® HYPER Technology Aug 13 2020 5:00 am UTC 60 mins
    Julius Ang
    Traditional 2D stacked vessels have been widely accepted as production platforms for vaccines, cell and gene therapies. However, there are limitations in providing good gas supply to all layers without active gassing. Large scale vessels are also bulky and require additional handling and incubator space. With proper considerations, these vessels can perform adequately, however, there is a need to increase product yields and improve process and operational efficiencies to meet evolving market demands.

    To address this need, Corning offers HYPER (High Yield PERformance) technology including HYPERFlask® and HYPERStack® cell culture vessels which brings a breath of fresh air to adherent cultures in conventional stacked vessels. In addition to improving operations, HYPER vessels can generate greater yields per volumetric footprint saving time, space and labor.

    In this webinar, learn more about Corning’s HYPER gas-permeable film technology and how this unique approach optimizes production value in the fields of cell and gene therapy.

    About the presenter:
    Julius is currently the Applications and Technical Support Manager for Greater Asia. He first started his career in biologics as an Upstream Scientist with Baxter and Lonza, both in Singapore and the United Kingdom. He then moved into regional commercial roles at Thermo Fisher Scientific and Merck supporting various upstream technologies and providing technical consultation to customers in Asia.

    Julius has extensive experience in cell line development, high throughput selection, media development, bioreactor evaluations and process transfer to large scales.
  • Calidad y Acreditación en Laboratorios Un Abordaje de la Influencia de Vidrios Recorded: Jul 22 2020 58 mins
    Jerónimo Figueiredo
    Calidad y Acreditación en Laboratorios - Un Abordaje de la Influencia de la Vidriería para Laboratorios
    Jerónimo Figueiredo - Business Operations Manager
  • がんオルガノイドを用いた抗がん剤の評価 Recorded: Jul 22 2020 77 mins
    公立大学法人 福島県立医科大学 ふくしま国際医療科学センター  医療-産業トランスレーショナルリサーチセンター セルファクトリー部門 教授 高木 基樹 先生
    がん組織より樹立した長期培養が可能な「がんオルガノイド(F-PDO®)」と「がん細胞株」とのゲノム、遺伝子発現、形態等の違い、がんオルガノイドの培養やアッセイ系構築の難しさ、がん細胞株(平面培養)との抗がん剤の感受性の違いなどについて紹介致します。

    <セミナーのポイント>
    ① がんオルガノイドの樹立と培養
    ② がんオルガノイドの特徴
    ③ がんオルガノイドを用いたアッセイ系構築のポイント
    ④ がんオルガノイドとがん細胞株の抗がん剤感受性の相違
  • General Guide to Cryogenically Storing Animal Cell Cultures Recorded: Jul 16 2020 38 mins
    Kyung-A (Katie) Song, Ph.D.
    Cells undergo several steps in culture from seeding to assay. However, researchers commonly face low cell viability, change in cell morphology, improper cell characterization or contamination during these steps. In addition, maintaining healthy growing cell cultures is difficult by the ever-present risk of their loss or change. These problems can be reduced by using cryogenic preservation to stop biological time in cell culture. This webinar will introduce general concepts of cryogenic storage of animal cell cultures.

    In this webinar, Kyung-A Song will review:
    •An introduction to cryogenic storage
    •Practical aspects of cell freezing
    •Troubleshooting for cryogenic storage


    Speaker Bio:
    Dr. Kyung-A Song graduated from Sungkyunkwan University with a Ph.D. in molecular biology and cancer immunology. She completed her postdoctoral fellowship in pharmaceutical research and drug discovery at Virginia Commonwealth University. She has extensive experience in a variety of cell culture techniques including isolation and culture of primary patient cells. She has worked with xenograft models and many cancer cell lines, and she has expertise in in vitro cell based functional assays and in vivo experiments. She is currently a Scientific Support Specialist for Corning Life Sciences where she answers customer inquiries about all products in the extensive Corning Life Sciences product portfolio.
  • Organoids Master Class: Brain Organoids & Their Application in Disease Modeling Recorded: Jul 14 2020 62 mins
    Richa Singhania, Ph.D., Director, Brain Organoid Core at Weill Cornell Medicine
    Our guest speaker, Richa Singhania, Ph.D., Director, Brain Organoid Core at Weill Cornell Medicine covers the following:

    Stem cell models of human brain: 1:54 - 4:37
    Cerebral organoids overview: 4:38 - 9:19
    Advances in brain organoid technology: 9:20 - 21:29
    Next generation organoid models: 21:30 - 27:39
    Applications of brain organoids in disease modeling: 27:40 - 29:54
    Modeling Glioblastoma in brain organoids: 29:54 - 43:24
    Understanding neurological effects of viruses: 43:25 - 46:22
    SARS-Cov-2 infection of brain organoids: 46:23 - 49:00
    The promise of brain organoids: 49:11 - 54:11
    Q&A Session: 54:12 - 1:01:04

    Speaker Bio:
    Richa is passionate about bringing precision medicine to the masses and make preclinical research successful to ultimately improve the lives of people affected by cancer. Richa has over 10 years of experience in translational cancer research, and her latest research is based on using stem cells and organoids for cancer modeling and drug discovery. Richa obtained a Masters in Biotechnology and PhD in Molecular Biology from University of Queensland, Australia. Thereafter, she completed postdoctoral fellowships at academic institutions in USA and UK. Currently, she is spearheading the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine, New York which integrates latest advances in organoid and automation technologies to create personalized solutions for brain cancer patients.
  • The Race for More Cells - Progress and Challenges in Maximizing Cell Densities Recorded: Jun 30 2020 59 mins
    Amit K Sharma
    Scientific progress in the cell and gene therapy field will accelerate clinical cell therapy programs in the coming years. As cell therapy trials advance from pre-clinical research to late-stage trials, cell culture platforms will need to meet increasing demands for cell yield and high cell densities while maintaining product quality and minimizing operating costs. To meet demand, traditional production methods that rely on planar cell culture vessels will require improvements in scale-out output, which can be quite tedious as a manual process.

    The challenge, then, becomes establishing an adherent culture platform that can effectively scale from relatively small needs of pre-clinical studies through Phase I/II trials and into Phase III. As a result, the ability to scale-out will ease the transition from process development to manufacturing.

    This webinar provides potential solutions that may be considered to improve cell density and productivity in adherent cell culture in the areas of vaccines and viral vector production. It will also highlight the perfusion-based Corning® CellCube® system as a flexible, modular method for maximizing cell and high titer retroviral vector yields.
  • Introducción al cultivo celular 3D Recorded: Jun 25 2020 57 mins
    Alfredo Javier Hernandez
    Alfredo Javier Hernandez- Account Manager Corning LifeSciences, maestro en ciencias especializado en biología celular
  • Rescheduled: Role of HUB Organoids in Treating Infectious Diseases Recorded: Jun 25 2020 45 mins
    Dr. Sylvia F. Boj, Chief Research Officer, Hubrecht Organoid Technology
    Key to the development of the Organoid Technology was the discovery of LGR5+ intestinal adult stem cells by the Clevers lab. When provided with the appropriate growth factors, HUB Organoids proved to be both genetically and phenotypically stable during prolonged periods of cell culture and are amenable to all standard experimental manipulations, including middle through-put drug screen.

    Because HUB Organoids can be generated from normal/healthy tissue and they maintain individual and tissue-specific characteristics, they have the potential to model viral infection diseases with relevant clinical implications such Hepatitis B (HBV), Respiratory Syncytial (RSV) and more recently Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2). At the same time, HUB Organoids can be used as a relevant patient model in (pre-)clinical phases to test effective drug treatments for infectious diseases, from which a relevant patient model was not available before.

    About the Presenter:
    Sylvia F Boj received her PhD in 2006 at the University of Barcelona, Spain for her work at IDIBAPS on functional genetic analysis for deciphering the transcriptional role of MODY genes in pancreatic beta cells.

    With a long term EMBO fellowship, she subsequently joined the Hubrecht Institute (Utrecht, the Netherlands) as a postdoctoral fellow. In the laboratory of Prof. Hans Clevers she first studied the role of TCF7L2 regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology (Utrecht, the Netherlands) as a group leader for Cystic Fibrosis and Cancer programs. In 2016, she was appointed as Scientific Director of HUB, with the ultimate goal of transferring scientific advances of the Organoid Technology to the development of new drugs, by interacting with pharmaceutical companies, and developing clinical trials to validate the predictive value of the Organoids for the response of patients.
Training for Life Science Researchers
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: ヒトiPS細胞由来高品質心筋細胞の大量作製法の開発と心臓再生医療への応用
  • Live at: Jun 23 2020 6:00 am
  • Presented by: 慶應義塾大学循環器内科 臓器再生医学寄附講座 特任講師 遠山周吾先生
  • From:
Your email has been sent.
or close